Compare AstraZeneca plc (AZN) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Orion Office REIT Inc — how do they compare? AstraZeneca plc trades at $158.59 (market cap $248.14B), while Orion Office REIT Inc trades at $2.76 (market cap $158.01M). The key difference: AstraZeneca plc is far larger — about 1570.4× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| AZN | ONL | |
|---|---|---|
Market Cap | $248.14B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $209.48 | $3.04 |
52-Week Low | $147.06 | $1.93 |
Enterprise Value | $275.41B | $574.95M |
Dividend Yield | 2.01% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
ONL trades at $2.76, up 0.36% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $0.42 versus -$0.07 expected, but maintains negative net income and ROE. Revenue has declined from $208M in 2022 to $148M in 2025, with a net loss of -$139M. Analyst consensus is split evenly between Buy and Hold.
The outlook remains challenged by persistent losses and declining revenue, though the low P/B of 0.25 suggests asset value. Key risks include high debt and weak profitability. Upside depends on successful portfolio repositioning and a return to sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
